Nivolumab plus Ipilimumab, with or without Enzalutamide, in AR-V7-expressing Metastatic Castration-Resistant Prostate Cancer: A Phase-2 Nonrandomized Clinical Trial

BACKGROUND: AR-V7-positive metastatic prostate cancer is a lethal phenotype with few treatment options and poor survival. METHODS: The two-cohort nonrandomized phase 2 study of combined immune checkpoint blockade for AR-V7–expressing metastatic castration-resistant prostate cancer (STARVE-PC) evalua...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Prostate
Main Authors: Shenderov, Eugene, Boudadi, Karim, Fu, Wei, Wang, Hao, Sullivan, Rana, Jordan, Alice, Dowling, Donna, Harb, Rana, Schonhoft, Joseph, Jendrisak, Adam, Carducci, Michael A., Eisenberger, Mario A., Eshleman, James R., Luo, Jun, Drake, Charles G., Pardoll, Drew M., Antonarakis, Emmanuel S.
Formato: Artigo
Idioma:Inglês
Publicado em: 2021
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8018565/
https://ncbi.nlm.nih.gov/pubmed/33636027
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pros.24110
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados